Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure

Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):157-66. doi: 10.1007/s00210-004-0963-0. Epub 2004 Sep 7.

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) increases contractile force and elicits arrhythmias through 5-HT(4) receptors in porcine and human atrium, but its ventricular effects are unknown. We now report functional 5-HT(4) receptors in porcine and human ventricle. 5-HT(4) mRNA levels were determined in porcine and human ventricles and contractility studied in ventricular trabeculae. Cyclic AMP-dependent protein kinase (PKA) activity was measured in porcine ventricle. Porcine and human ventricles expressed 5-HT(4) receptor mRNA. Ventricular 5-HT(4(b)) mRNA was increased by four times in 20 failing human hearts compared with five donor hearts. 5-HT increased contractile force maximally by 16% (EC(50)=890 nM) and PKA activity by 20% of the effects of (-)-isoproterenol (200 microM) in ventricular trabeculae from new-born piglets in the presence of the phosphodiesterase-inhibitor 3-isobutyl-1-methylxanthine. In ventricular trabeculae from adult pigs (3-isobutyl-1-methylxanthine present) 5-HT increased force by 32% (EC(50)=60 nM) and PKA activity by 39% of (-)-isoproterenol. In right and left ventricular trabeculae from failing hearts, exposed to modified Krebs solution, 5-HT produced variable increases in contractile force in right ventricular trabeculae from 4 out of 6 hearts and in left ventricular trabeculae from 3 out of 3 hearts- range 1-39% of (-)-isoproterenol, average 8%. In 11 left ventricular trabeculae from the failing hearts of four beta-blocker-treated patients, pre-exposed to a relaxant solution with 0.5 mM Ca(2+) and 1.2 mM Mg(2+) followed by a switch to 2.5 mM Ca(2+) and 1 mM Mg(2+), 5-HT (1-100 microM, 3-isobutyl-1-methylxanthine present) consistently increased contractile force and hastened relaxation by 46% and 25% of (-)-isoproterenol respectively. 5-HT caused arrhythmias in three trabeculae from 3 out of 11 patients. In the absence of phosphodiesterase inhibitor, 5-HT increased force in two trabeculae, but not in another six trabeculae from 4 patients. All 5-HT responses were blocked by 5-HT(4) receptor antagonists. We conclude that phosphodiesterase inhibition uncovers functional ventricular 5-HT(4) receptors, coupled to a PKA pathway, through which 5-HT enhances contractility, hastens relaxation and can potentially cause arrhythmias.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • Adolescent
  • Adult
  • Aged
  • Animals
  • Cardiotonic Agents / therapeutic use*
  • Cyclic AMP-Dependent Protein Kinases / drug effects
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Female
  • Free Radical Scavengers / pharmacology*
  • Heart Ventricles / drug effects*
  • Heart Ventricles / enzymology
  • Humans
  • Isoproterenol / therapeutic use*
  • Male
  • Middle Aged
  • Myocardial Contraction / drug effects*
  • Myocardial Ischemia / drug therapy
  • Myocardial Ischemia / enzymology*
  • Phosphodiesterase Inhibitors / pharmacology
  • RNA, Messenger / genetics*
  • RNA, Messenger / isolation & purification
  • Receptors, Serotonin, 5-HT4 / genetics
  • Serotonin / pharmacology
  • Serotonin / physiology*
  • Serotonin 5-HT4 Receptor Antagonists*
  • Swine
  • Ventricular Function

Substances

  • Cardiotonic Agents
  • Free Radical Scavengers
  • Phosphodiesterase Inhibitors
  • RNA, Messenger
  • Serotonin 5-HT4 Receptor Antagonists
  • Receptors, Serotonin, 5-HT4
  • Serotonin
  • Cyclic AMP-Dependent Protein Kinases
  • Isoproterenol
  • 1-Methyl-3-isobutylxanthine